CRO Quality Charcoal DFI Ocular tolerability Phase I Unit CDM IEC Gynaecological trials HTA ICF Phase I Steady state Hypothalamic AGAH Clinical trials Postmenopausal women Ophthalmologist Xerostomia Pharmacokinetics Children DUS GCP training Drug Food Interaction In vitro in vivo correlation US FDA EMA Hormone replacement therapy Post authorisation Phase II Life cycle management Rhine Main area Local tolerability Clinical study ANVISA Early phase Common cold Design development Eye disease Feasibility Auditing Expert Thuringia Good Clinical Practice Dry powder inhaler Cough DDI Data management Training Data Management Plan Female adolescents Endpoint Monitoring US CFR 21 Part 11 Healthy subjects Dermal irritation CDISC CRA Contraception IVIVC Pilot study Authorities Recruitment rates PAES Metered dose inhaler Allergy Transdermal therapeutic system Dry eye Legal Information Scientific advice Adrenocortical Cardiovascular surveillance First in human Axis Quality Assurance Experience Protocol PASS Scientific expertise Spacious archive Database DPI CDASH Subcontractor qualification Phase IIa trials Oncologic network Centralised procedure WinNonlin Pharmacodynamic studies Non interventional Inhalatives Creativity Project Management Bioequivalence Patch adhesion Legal representative Investigators brochure Biopharmaceutics Sample size estimation Edema Biopharmaceutical Ophthalmology HRT Clinical pharmacology unit SocraTec C&S IMPD Product development MMM Absorption Source Data Verification Pharmacology Pragmatism COPD Audit Bioavailability HPA axis NIS Sensitisation trials Pituitary Immunogenicity Clinical development program Data Validation Plan Pharmacokintetics Uveitis Ovulation inhibition CRF Safety FIM Sore throat Oncology Macular Oncological patients Slit lamp microscopy Patient recruitment Patients MCID Statistical programming Statistical services OTC Ophthalmological trials Glaucoma Asthma Anaesthesiologist IB Biosimilars Consultancy Protocol development Clinical Monitoring Inspection Lung SAS Competence Elpro Informed Consent Procedure Intensive assessment station Efficacy TTS GLP Paediatricians CDSIC Patch Phase IV Pulse oximetry plethysmography Drug Drug Interaction Biometrics Highly variable drugs Quality Management System ADAM Referral system Standard operating procedure Phase III Statistical Analysis Plan SDV Phase IIb trials SOP based Sequential designs MDI Standardisation FDA GCP Degeneration Copyright Network Absorption windows Dose linearity Central surveillance system
Box 0
Design Development
Box 1
Scientific Advice
Box 2
Project Management
Box 3
Quality Assurance (QA)
Box 4
Box 5
Clinical Performance
Box 6
Data Management / eTrials
Box 7
Box 8
Medical Writing
Box 9
Expert Statement
Box 10
Box 11
Box 12
Bioavailability / Bioequivalence
Box 13
Box 14
Oncological trials
Box 15
Ophthalmological trials
Box 16
Box 17
Transdermal Therapeutic Systems
Box 18
Box 19
Sexual Hormones
Box 20
Therapeutic Expertise
Box 21
Clinical Development
Box 22
Phase I
Box 23
Phase II / Proof of Concept
Box 24
Phase III in OTC
Box 25
Phase III
Box 26
Box 27
Magnetic Marker Monitoring
Box 28
Medical Devices
Box 29
Nutrition Studies
Box 30
Clinical Pharmacology Unit
Box 31
Location Plan
Box 32
Box 33
Technical Monitoring
Box 34
Box 35
Box 36
Intensive Assessment Unit
Box 37
Clean Room Area
Box 38
Box 39
About Us
Box 40
Goals and Visions
Box 41
Our Experts
Box 42
Box 43
Box 44
Library Presentations
Box 45
Library Publications
Box 46
Box 47
Box 48
Box 49
German Pharm-Tox Summit 2017 in Heidelberg
Box 50
2nd part of Introductory Course in Explorator...
Box 51
Introductory Course in Exploratory Medicines ...
Box 52
2nd Global Bioequivalence Harmonisation Initi...
Box 53
Quality Management Systems in Early Phase Tri...
Box 54
Trial in drug-induced xerostomia published
Box 55
Box 56
The SocraTec Family
Box 57
SocraTec C&S
Box 58
Box 59
Box 60

All fine on front page